Extra Domain B-Fibronectin Targeted Ultrasound Contrast Agents for Pancreatic Cancer Diagnosis
Issued Date
2025-01-01
Resource Type
ISSN
19485719
eISSN
19485727
Scopus ID
2-s2.0-105021824856
Journal Title
IEEE International Ultrasonics Symposium Ius
Rights Holder(s)
SCOPUS
Bibliographic Citation
IEEE International Ultrasonics Symposium Ius (2025)
Suggested Citation
Kosmides T., Nittayacharn P., Gao S., Lu Z.R., Exner A. Extra Domain B-Fibronectin Targeted Ultrasound Contrast Agents for Pancreatic Cancer Diagnosis. IEEE International Ultrasonics Symposium Ius (2025). doi:10.1109/IUS62464.2025.11201329 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113172
Title
Extra Domain B-Fibronectin Targeted Ultrasound Contrast Agents for Pancreatic Cancer Diagnosis
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Pancreatic cancer is the sixth leading cause of global cancer related death with a rising incidence projected as ~1M new cases by 2050 [1]. Most patients present with non-resectable pancreatic ductal adenocarcinoma (PDAC), resulting in a global five-year survival rate of 10% [1]. To increase treatment options, more effective early PDAC detection tools are needed. Endoscopic and transabdominal ultrasound (US) are frequently used in PDAC diagnosis. In this work, we aim to improve US-based PDAC diagnostic sensitivity by developing a sub-micron contrast agent targeting extra domain B-fibronectin (EDB-FN), a biomarker overexpressed in PDAC [2]. To address these challenges, we propose the addition of ZD2, an EDB-FN targeted molecule, to increase PDAC signal intensity, thus improving diagnosis. The EDB-FN targeted peptide, ZD2, was successfully incorporated into lipid shell stabilized, C<inf>3</inf>F<inf>8</inf> core nanobubble (NB) contrast agents (ZD2-NB) without significantly altering agent size or echogenicity. The peptide retained its ability to interact with the target (EDB-FN) after incorporation into the contrast agent; significantly increasing the in vitro retention of ZD2-NBs in Capan-1 and BxPC3 cells compared to untargeted NBs. Finally, ZD2-NBs resulted in higher nonlinear contrast (NLC) signal intensity (maximum 123x, mean 12x) compared to untargeted NBs in a murine flank PDAC tumor model. The ZD2-NBs had a slower washout in EDB-FN+ tumors compared to untargeted NBs (maximum 13x, mean 4x). The data demonstrate that ZD2-NBs have higher NLC signal intensity and longer retention in EDB-FN+ tumors, suggesting their utility as an US-based early PDAC detection method.